Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) prior to bariatric surgery was safe but wasn’t associated with ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

A new study reveals patients may continue to take their GLP-1 receptor agonists before undergoing elective surgery or ...

While there are hundreds of methods to make the scale move, many cost hundreds of dollars. That’s why Amazon shoppers are ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Smoothie King just launched its GLP-1 Support Menu with five specific smoothie blends to help support the journey of individuals using GLP-1 weight loss medications like Ozempic and Wegovy – and ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 ...